Overall survival data from a 3-arm, randomized, open-label, phase 2 study of relacorilant, a selective glucocorticoid receptor modulator, combined with nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.
| Image |  |
|---|---|
| Description | scientific article published in 2022 |
| Author/s |
author: Ursula A. Matulonis Nicoletta Colombo Domenica Lorusso Rachel N. Grisham |
| Publication date | June 10, 2022 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |